title: [TPS and SCC antigens in diagnosis and monitoring treatment of patients with cervical cancer].
abstract: METHODS
  The purpose was to evaluate the usefulness of serum TPS and SCC assay for the monitoring radiotherapy of patients with cervical cancer.
  
  
  METHODS
  38 patients with cervical cancer treated with radiotherapy were included in this study. The concentrations of TPS and SCC were determined prior to radiotherapy, after radiotherapy, 3 and 6 months after radiotherapy.
  
  
  RESULTS
  The increase in TPS levels prior to treatment was observed in serum of 80% women, SCC rose by 71%. The frequency of increased results and absolute value of TPS levels showed tendency to significant increase together with development of disease and degree of histological differentiation. A significant decrease of TPS and SCC level was observed during radiotherapy. The TPS levels decreased above cut-off values in all patients, SCC in 90% patients with remission after radiotherapy. In cases of patients who still had high TPS antigen level after treatment, progression of cancer was found.
  
  
  CONCLUSIONS
  These results suggest that TPS and SCC are useful in monitoring treatment of patients with cervical cancer.
authors.affiliation: Zakład Laboratoryjnej Diagnostyki Klinicznej Akademii Medycznej w Białymstoku.
authors.forename: I
authors.initials: I
authors.lastname: Zakrzewska
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D012680:Sensitivity and Specificity; D015843:Serpins; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000532:radiotherapy
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D010455:Peptides; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; C089984:tissue polypeptide specific antigen